Prostate Cancer - Results from #300

Moderately hypofractionated prostate-only versus whole-pelvis radiotherapy for high-risk prostate cancer: A retrospective real-world single-center cohort study. September 12, 2024

Silver Nanoparticles (AgNPs) Uptake by Caveolae-Dependent Endocytosis is Responsible for Their Selective Effect Towards Castration Resistant Prostate Cancer. September 12, 2024

Oncologic Outcomes of Incidental Versus Biopsy-diagnosed Grade Group 1 Prostate Cancer: A Multi-institutional Study. September 12, 2024

Amiloride Sensitizes Prostate Cancer Cells to the Reversible Tyrosine Kinase Inhibitor Lapatinib by Modulating ERBB3 Subcellular Localization. September 12, 2024

Study Confirms AI Outperforms Conventional Methods for Prostate Cancer Extracapsular Extension Detection, Offering More Accurate Risk Assessments for Surgical Decisions September 11, 2024

Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm September 11, 2024

Testosterone recovery after androgen deprivation therapy. September 11, 2024

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial. September 11, 2024

Hospital-Level Variability in the Adoption of Image-Guided Focal Therapy for Localized Prostate and Kidney Cancer. September 11, 2024

Prevention of Prostate Cancer Metastasis by a CRISPR-delivering Nanoplatform for Interleukin-30 Genome Editing. September 11, 2024

The Impact of Radical Prostatectomy Versus Radiation Therapy on Cancer-Specific Mortality for Nonmetastatic Prostate Cancer: Analysis of an Other-Cause Mortality Matched Cohort. September 11, 2024

Artificial Intelligence Improves the Ability of Physicians to Identify Prostate Cancer Extent. September 11, 2024

A new silicon phthalocyanine dye induces pyroptosis in prostate cancer cells during photoimmunotherapy. September 10, 2024

Emergency and non-emergency routes to cancer diagnoses in 2020 and 2021: A Population-based study of 154,863 patients. September 10, 2024

Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial. September 10, 2024

Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study. September 10, 2024

Predictive factors of hemoglobin drop after robot-assisted radical prostatectomy: a single center prospective study. September 10, 2024

Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer. September 9, 2024

Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing. September 9, 2024

Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis. September 9, 2024

Page 16 of 1436